Combination therapy with anti-HIV-1 antibodies maintains viral suppression

HIV-1-infected individuals require lifelong antiretroviral therapy (ART) because treatment interruption leads to rapid rebound viremia. Here we report on a phase 1b clinical trial in which a combination of 3BNC117 and 10–1074, two potent monoclonal anti-HIV-1 broadly neutralizing antibodies that tar...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Nature
Prif Awduron: Mendoza, Pilar, Gruell, Henning, Nogueira, Lilian, Pai, Joy A., Butler, Allison L., Millard, Katrina, Lehmann, Clara, Suárez, Isabelle, Oliveira, Thiago Y., Lorenzi, Julio C.C., Cohen, Yehuda Z., Wyen, Christoph, Kümmerle, Tim, Karagounis, Theodora, Lu, Ching-Lan, Handl, Lisa, Unson-O’Brien, Cecilia, Patel, Roshni, Ruping, Carola, Schlotz, Maike, Witmer-Pack, Maggi, Shimeliovich, Irina, Kremer, Gisela, Thomas, Eleonore, Seaton, Kelly E., Horowitz, Jill, West, Anthony P., Bjorkman, Pamela J., Tomaras, Georgia D., Gulick, Roy M., Pfeifer, Nico, Fätkenheuer, Gerd, Seaman, Michael S., Klein, Florian, Caskey, Marina, Nussenzweig, Michel C.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2018
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6166473/
https://ncbi.nlm.nih.gov/pubmed/30258136
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41586-018-0531-2
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg